Verrica Pharmaceuticals (VRCA) said Wednesday it is restructuring its sales and operating teams aimed at reducing costs and expanding access to YCANTH for the treatment of molluscum contagiosum.
The restructuring is expected to lower the company's overall cost structure by around 50% while maintaining adequate resources to support its primary product, YCANTH.
Verrica said it will reduce its number of sales territories from 80 to 35, focusing on regions with a high prevalence of molluscum contagiosum, substantial usage of cantharidin, which is the active ingredient in YCANTH, and strong insurance coverage for the product.
In addition, sales efforts will target both pediatricians and dermatologists to enhance access to YCANTH.
Verrica anticipates a one-time restructuring charge of around $1 million.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。